Jump to main content
Jump to site search

Issue 11, 2015
Previous Article Next Article

Targeting copper in cancer therapy: ‘Copper That Cancer

Author affiliations

Abstract

Copper is an essential micronutrient involved in fundamental life processes that are conserved throughout all forms of life. The ability of copper to catalyze oxidation–reduction (redox) reactions, which can inadvertently lead to the production of reactive oxygen species (ROS), necessitates the tight homeostatic regulation of copper within the body. Many cancer types exhibit increased intratumoral copper and/or altered systemic copper distribution. The realization that copper serves as a limiting factor for multiple aspects of tumor progression, including growth, angiogenesis and metastasis, has prompted the development of copper-specific chelators as therapies to inhibit these processes. Another therapeutic approach utilizes specific ionophores that deliver copper to cells to increase intracellular copper levels. The therapeutic window between normal and cancerous cells when intracellular copper is forcibly increased, is the premise for the development of copper-ionophores endowed with anticancer properties. Also under investigation is the use of copper to replace platinum in coordination complexes currently used as mainstream chemotherapies. In comparison to platinum-based drugs, these promising copper coordination complexes may be more potent anticancer agents, with reduced toxicity toward normal cells and they may potentially circumvent the chemoresistance associated with recurrent platinum treatment. In addition, cancerous cells can adapt their copper homeostatic mechanisms to acquire resistance to conventional platinum-based drugs and certain copper coordination complexes can re-sensitize cancer cells to these drugs. This review will outline the biological importance of copper and copper homeostasis in mammalian cells, followed by a discussion of our current understanding of copper dysregulation in cancer, and the recent therapeutic advances using copper coordination complexes as anticancer agents.

Graphical abstract: Targeting copper in cancer therapy: ‘Copper That Cancer’

Back to tab navigation

Publication details

The article was received on 05 Jun 2015, accepted on 07 Aug 2015 and first published on 21 Aug 2015


Article type: Critical Review
DOI: 10.1039/C5MT00149H
Author version
available:
Download author version (PDF)
Citation: Metallomics, 2015,7, 1459-1476

  •   Request permissions

    Targeting copper in cancer therapy: ‘Copper That Cancer

    D. Denoyer, S. Masaldan, S. La Fontaine and M. A. Cater, Metallomics, 2015, 7, 1459
    DOI: 10.1039/C5MT00149H

Search articles by author

Spotlight

Advertisements